Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **glucose absorption pathway** refers to the coordinated process by which dietary carbohydrates are digested and the resulting monosaccharide, primarily **glucose**, is absorbed from the lumen of the small intestine into the bloodstream. This is not a single molecular target but rather a physiological process involving multiple membrane transport proteins. The two main molecular components mediating this process in enterocytes are: • **Sodium-glucose cotransporter 1** (**SGLT1**): Located on the apical membrane of intestinal epithelial cells, SGLT1 uses secondary active transport—coupling one molecule of glucose with two sodium ions—to move glucose from the gut lumen into enterocytes against its concentration gradient[1][4][6]. • **Glucose transporter type 2** (**GLUT2**): Found mainly on the basolateral membrane, GLUT2 facilitates passive diffusion of intracellular glucose into portal circulation. Under high luminal concentrations, GLUT2 can also be recruited to the apical surface for additional absorptive capacity[1][4]. This pathway is essential for maintaining systemic energy balance and regulating postprandial glycemia. Disruption or pharmacologic inhibition can lead to significant metabolic consequences; for example, genetic defects in SGLT1 cause severe congenital malabsorption syndromes[1]. Drugs targeting this pathway aim to modulate post-meal blood sugar spikes by inhibiting key transporters. Because "Glucose absorption pathway" describes an entire biological process rather than a discrete therapeutic target such as an enzyme or receptor protein, it should not be considered a canonical drug target entity. Instead, individual components like "Sodium-glucose cotransporter 1" or "Glucose transporter type 2" represent valid molecular targets within this broader physiological context[3][6].
Inhibition of sodium-glucose cotransport to reduce intestinal glucose uptake and lower postprandial blood sugar levels[4]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucose absorption pathway.